Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Eliquis (apixaban), Pradaxa (dabigatran etexilate), Xarelto (rivaroxaban) - Important Safety Information from Bristol-Myers Squibb Pharmaceuticals/Pfizer EEIG, Boehringer Ingelheim, Bayer Pharma AG as approved by the Irish Medicines Board
Notice type:
3rd Party Publications
Date:
13/09/2013
Problem Or Issue:
Important Safety Information communication from Bristol-Myers Squibb Pharmaceuticals/Pfizer EEIG, Boehringer Ingelheim and Bayer Pharma AG on the risk factors for bleeding, monitoring of posology, contraindications, warnings and precautions for use to reduce the risk of bleeding for Eliquis (apixaban), Pradaxa (dabigatran etexilate), Xarelto (rivaroxaban).
Important Safety Information - Eliquis (apixaban), Pradaxa (dabigatran etexilate), Xarelto (rivaroxaban)
« Back
Date Printed: 07/05/2024